Loading...
OTCM
TRUMY
Market cap21bUSD
Oct 08, Last price  
13.25USD
1D
-9.65%
1Q
-2.47%
Jan 2017
-28.35%
Name

Terumo Corp

Chart & performance

D1W1MN
OTCM:TRUMY chart
P/E
22.72
P/S
2.73
EPS
92.14
Div yield, %
—
Shrs. gr., 5y
-0.51%
Rev. gr., 5y
13.02%
Revenues
1.13t
+9.24%
276,439,000,000306,381,000,000302,746,000,000316,009,000,000328,214,000,000386,686,000,000402,294,000,000467,359,000,000489,506,000,000525,026,000,000514,164,000,000587,775,000,000599,481,000,000628,897,000,000613,842,000,000703,303,000,000820,209,000,000921,863,000,0001,036,171,000,0001,131,877,000,000
Net income
135.91b
+16.19%
37,232,000,00043,382,000,00036,878,000,00040,721,000,00032,338,000,00024,167,000,00047,014,000,00034,096,000,00038,470,000,00050,676,000,00054,225,000,00091,295,000,00079,470,000,00085,211,000,00077,268,000,00088,813,000,00089,325,000,000106,374,000,000116,978,000,000135,914,000,000
CFO
230.85b
+9.51%
43,123,000,00069,683,000,00031,615,000,00067,352,000,00046,828,000,00056,200,000,00050,270,000,00096,259,000,00073,110,000,00080,303,000,00080,862,000,000114,562,000,00093,571,000,000117,479,000,000121,485,000,000141,467,000,000117,536,000,000146,330,000,000210,802,000,000230,852,000,000
Dividend
Sep 29, 20260.11557 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Terumo Corporation is a global enterprise dedicated to the development, manufacturing, and distribution of a wide array of medical products and equipment. Its comprehensive operations are structured across three primary divisions: the Cardiac and Vascular Company, the Medical Care Solutions Company, and the Blood and Cell Technologies Company. The Cardiac and Vascular Company focuses on cardiovascular and neurovascular interventions. Its product portfolio encompasses a variety of devices, including angiographic guidewires, catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, and self-expanding peripheral stents, alongside advanced intravascular ultrasound systems and imaging catheters. This division also develops specialized devices for treating cerebral aneurysms, such as coils, stents, and intrasaccular devices, as well as embolization systems, aspiration catheters, and clot retrievers for ischemic stroke. Furthermore, it supplies critical components for cardiac surgery, including oxygenators and cardio-pulmonary bypass systems, in addition to artificial vascular and stent grafts. The Medical Care Solutions Company addresses a broad spectrum of general medical and patient care needs. Offerings include essential medical supplies like syringes, infusion and syringe pumps, infusion lines, I.V. solutions, peritoneal dialysis fluids, and products for pain management and nutritional support, as well as adhesion barriers. This segment also produces consumer health monitoring devices such as blood glucose monitoring systems, disposable needles for pen-injectors, insulin patch pumps, blood pressure monitors, and digital thermometers. Moreover, it provides contract manufacturing services for pharmaceutical companies, specializing in prefilled syringes and devices like prefillable syringes and needles for pharmaceutical packaging. Finally, the Blood and Cell Technologies Company concentrates on products and systems for blood and cell management. Its offerings span blood bags, component collection systems, automated blood processing systems, pathogen reduction systems, centrifugal apheresis systems, and advanced cell expansion systems. Established in 1921, the company was initially known as Sekisen Ken-onki Corporation before adopting its current name, Terumo Corporation, in October 1974. Terumo Corporation maintains its corporate headquarters in Tokyo, Japan.

Related entities

Subsidiaries (3)
Terumo BCT Europe
TERUMO EUROPE
VASCUTEK LIMITED

Key people

Miho Mizuguchi
Executive Officer, Chief Legal Officer(CLO), Manager of CLO Office · since 2023
Toshio Nakashima
Executive Officer, Manager of Aitaka Plant in Cardiac and Vascular Company, Deputy Chief Operations Officer (COO) of TIS Business in Cardiac and Vascular Company · since 2022
Cindy Ng
Group Executive Officer, Senior Vice Presidentof Global Commercial of Blood and Cell Technologies Company · since 2025
Shinji Omori
Chief Technology Officer, Executive Officer, Manager of R&D Center · since 2025
Erik Pomp
Executive Officer, President of the Vascular Business in Cardiac and Vascular Company, CEO of Terumo Aortic · since 2022
James Rushworth
Executive Officer, Chief Commercial Officer (CCO) of TIS Business in Cardiac & Vascular Company, President & Chief Executive Officer of Subsidiary · since 2022
Sakae Sasaki
Executive Officer · since 2025
Carsten Schroeder
Executive Officer, President of Neurovascular Business in Cardiovascular Company, CEO of Subsidiary · since 2022
Takumi Uchida
Executive Officer, Chief Operations Officer (COO) of Medical Care Solutions Company · since 2024
Chris Williams
Group Executive Officer, Senior Vice President of Global Manufacturing in Blood and Cell Technologies Company · since 2024
Jun Yamashita
Executive Officer, Chief Quality Officer · since 2024
Masanobu Yano
Group Executive Officer · since 2025
Hikaru Samejima
President, Chief Executive Officer, Representative Director · since 2024
Takanori Shibazaki
Director · since 2021
Toshiaki Takagi
Chairman of the Board, Representative Director · since 2022
Mari Kogiso
Independent Director · since 2024
Hidenori Nishi
Independent Director · since 2020
Keiya Ozawa
Independent Director · since 2021
Soichiro Uno
Independent Director · since 2019
IPO date
Jun 21, 1982
Employees
30,207
Domiciled in
JP
Incorporated in
JP
Headquarters & legal address
幡ヶ谷二丁目44番1号
東京都 渋谷区 151-0072
JP
Address
2-44-1, Hatagaya
Shibuya-ku Tokyo 151-0072
JP
Other language
Terumo Corporation

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑032025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT